Table 3.

Changes in Lipid Parameters After 6 to 8 Weeks of Treatment but Before Endotoxin

	Randomization	Before LPS	Absolute Δ	P*
Total cholesterol, mg/dL
Fenofibrate	170.3±34.5	136.9±30.8	−33.4±18.2	0.0094
Placebo	177.4±39.4	160.9±35.0	−16.4±18.6
LDL cholesterol, mg/dL
Fenofibrate	96.0±28.7	72.6±28.4	−23.4±14.2	0.0014
Placebo	97.6±39.3	92.3±32.4	−5.4±16.9
TGs, mg/dL
Fenofibrate	78.0±39.8	57.0±22.5	−21.0±38.9	0.41†
Placebo	91.6±46.1	76.7±32.9	−14.9±31.7
HDL cholesterol, mg/dL
Fenofibrate	58.7±17.0	52.9±13.4	−5.8±9.1	0.50
Placebo	61.4±18.2	53.3±15.6	−8.1±10.7
Apolipoprotein A-I, mg/dL
Fenofibrate	139.0±38.9	117.8±23.5	−21.1±22.1	0.64
Placebo	149.6±36.8	125.2±33.5	−24.4±19.6
Apolipoprotein B, mg/dL
Fenofibrate	74.4±21.8	55.1±19.2	−19.3±13.2	0.0079
Placebo	76.7±30.4	68.8±23.5	−7.9±10.5
Phospholipids, mg/dL
Fenofibrate	192.6±34.5	165.6±26.6	−27.0±24.0	0.61
Placebo	206.1±45.3	183.2±33.9	−22.9±23.7

Values are given as mean±standard deviation. LPS indicates lipopolysaccharide; LDL, low-density lipoprotein; TGs, plasma triglycerides; and HDL, high-density lipoprotein.

^*P values obtained from 2-sided Student t test comparing absolute change from baseline to before LPS administration by treatment group.

^†Raw data are presented, but log-transformed data were used in analysis.